IMA-950

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameIMA-950
Drug Alias NameGlioblastoma vaccineIMA-950
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsBrevican core proteinChondroitin sulfate proteoglycan 4Neuroligin-4, X-linked +[8] 
Therapy Area/IndicationsCNS Embryonal TumorCentral Nervous System NeoplasmsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmatics Biotechnologies Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmatics Biotechnologies Gmbh
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorCentral Nervous System NeoplasmsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A